drugset
drugset / Trial / NCT06660017

Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse

NCT06660017 ↗

Phase 2 Not yet recruiting 62 enrolled University of Oklahoma
RandomizedParallel-groupSingle-blindTreatment

Summary

This 2-arm phase II study proposes to determine the efficacy of ketamine oral rinse in pain relief from mucositis in head and neck cancer patients undergoing radiation treatment.

Timeline

Start
2026-06
Primary completion
2027-06
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 20 mg Topical

Indications

head and neck cancer